{"id":391164,"date":"2016-04-08T00:00:00","date_gmt":"2016-04-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0007-2016-biopharma-rheumatoid-arthritis-unmet-need-us-eu-2016\/"},"modified":"2026-04-25T23:25:06","modified_gmt":"2026-04-25T23:25:06","slug":"unneim0007-2016-biopharma-rheumatoid-arthritis-unmet-need-us-eu-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0007-2016-biopharma-rheumatoid-arthritis-unmet-need-us-eu-2016\/","title":{"rendered":"Rheumatoid Arthritis | Unmet Need | US\/EU | 2016"},"content":{"rendered":"<p>Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral Jak inhibitor Xeljanz (Pfizer). Given rheumatologists\u2019 long-standing familiarity with the safety and efficacy profiles of the TNF-alpha inhibitors and non-TNF-alpha biologics Orencia (Bristol-Myers Squibb), Rituxan\/MabThera (Biogen\/Roche), and RoActemra\/Actemra (Roche), new agents face formidable challenges in gaining uptake in this crowded market. Nonetheless, all marketed RA drugs are associated with substantial nonresponder rates, highlighting a significant unmet need and commercial opportunity for novel therapies that can offer improved efficacy and safety.<\/p>\n","protected":false},"template":"","class_list":["post-391164","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391164\/revisions"}],"predecessor-version":[{"id":394287,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391164\/revisions\/394287"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}